The company's technology relies on protein engineering and evolution to discover new targets and develop drugs for autoimmune diseases, chronic infections, and cancer. Nextera's strategy is to differentiate from competitors by focusing on high-resolution target discovery and lead candidate development in HLA class II associated mechanisms. The company also includes a companion diagnostic for all leads developed. Nextera aims to modulate the disease at the core of the immune cascade to provide disease-specific treatment without compromising systemic immunity. The company collaborates with partners to jointly develop therapies for complex diseases in major indications that are difficult to treat.